

**Correction to  
Lancet Oncol 2014;  
15: 1503–12**

Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncol* 2014; **15**: 1503–12—In the eighth paragraph of the Results section of this Article, the first sentence should have been “Overall responses were noted in 59 (92%, 95% CI 83–97) of 64 patients (table 5)”. This correction has been made to the online version as of July 1, 2019.

**Correction to  
Lancet Oncol 2019;  
20: 765**

Ben-Aharon I, Goshen-Lago T, Fontana E, et al. Social networks for young patients with cancer: the time for system agility. *Lancet Oncol* 2019; **20**: 765—In this Perspectives article, Marianne Guren and Carmela Caballero should be listed as separate authors in the author list and affiliations. This correction has been made to the online version as of July 1, 2019.

**Correction to  
Lancet Oncol 2019;  
20: 769–80**

Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. *Lancet Oncol* 2019; **20**: 769–80—In the affiliations for this Article, Dr Mei Ling Yap should have been affiliated with the University of New South Wales (Sydney, NSW, Australia). This correction has been made to the online version as of July 1, 2019.

**Correction to  
Lancet Oncol 2019;  
20: 795–805**

Hofvind S, Holen AS, Aase HS, et al. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. *Lancet Oncol* 2019; **20**: 795–805—In figure 1, the number of patients with screen-detected breast cancer in the digital breast tomosynthesis group should have read 95, and the number of patients in the digital mammography group should have read 87. Additionally, patients with bilateral breast cancer are now included as a subgroup of the patients with screen-detected breast cancer. These corrections have been made to the online version as of July 1, 2019.

**Correction to  
Lancet Oncol 2019;  
20: 986–99**

Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2019; **20**: 986–99—In this Article, the second sentence in the Statistical analysis section should have read “The sample size calculation wording in the original protocol specified a 5%, two-sided calculation; however, this wording was inaccurate, and subsequently, a one-sided calculation at 2.5% was implemented to solely test for superiority of quizartinib, which is consistent with the primary aim of the study.” This correction has been made to the online version as of July 1, 2019, and the printed Article is correct.

**Correction to  
Lancet Oncol 2019;  
20: e302–12**

Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncol* 2019; **20**: e302–12—The author listed as Eloísa Riva Serra of this paper should be listed as Eloísa Riva in the author list. ER Serra should be E Riva in the affiliations. ERS should be ER in the declaration of interests statement. These corrections have been made to the online version as of July 1, 2019.